Filter
Therapeutic AreaRegionDeal TypeNon Pharma
Anwenden
array(1) { [0]=> object(WP_Term)#4385 (16) { ["term_id"]=> int(68) ["name"]=> string(12) "Transactions" ["slug"]=> string(15) "transactions-de" ["term_group"]=> int(0) ["term_taxonomy_id"]=> int(68) ["taxonomy"]=> string(8) "category" ["description"]=> string(385) "To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle. Please find below selected transactions completed by WINDOME BANKING PARTNERS' employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023)." ["parent"]=> int(0) ["count"]=> int(73) ["filter"]=> string(3) "raw" ["cat_ID"]=> int(68) ["category_count"]=> int(73) ["category_description"]=> string(385) "To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle. Please find below selected transactions completed by WINDOME BANKING PARTNERS' employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023)." ["cat_name"]=> string(12) "Transactions" ["category_nicename"]=> string(15) "transactions-de" ["category_parent"]=> int(0) } }
August 2006

Divestiture of Pharmaton SA, Lugano and Boehringer Ingelheim’s worldwide Natural Health Phyto-based Nutraceuticals, Vitamins and Mineral Supplements to Amway.

Undisclosed terms.
Januar 2006

Completed divestiture of Boehringer Ingelheim’s ectoparasiticides Animal Health Business to Elanco.

US$ 30m upfront Payment.
Dezember 2005

Completed divestiture of a broad-spectrum antibiotic (“Romifidine”) for feed use in Animal Health.

Undisclosed terms.
November 2005

Completed divestiture of Boehringer Ingelheim’s and SSP’s portfolio of Korean and Japanese subsidiaries.

Undisclosed terms.
März 2005

Completed divestiture via carve-out of Nippon Boehringer Ingelheim’s prescription generics business in Japan (Total sales €100m in 2003) including a guarantee payment by Boehringer Ingelheim for a 2 Year post-closing employment continuation.

¥ 20.2bn Total enterprise value.
Dezember 2004

Completed the 100% acquisition of German respiratory medical devices company Steag MicroParts GmbH, Dortmund.

€ 50m Total enterprise value.
November 2004

Completed the divestiture of 5 US OTC Natural Health multivitamin brands to Bayer AG.

Undisclosed terms.
Mai 2004

Completed acquisition of ID Lelystad’s Animal Health vaccine business.

Undisclosed terms.
November 2003

Completed acquisition of Novartis’s OTC Laxative brand Dulcolax.

€ 80m Upfront and milestone purchase price.
März 2003

Exclusive financial advisor to MorphoSys in signing collaboration partnership with Boehringer Ingelheim.

€ 15m Upfront payment.
Februar 2003

Exclusive financial advisor in the acquisition of a minority equity stake in Incisive Genetics.

Undisclosed terms.
Oktober 2001

Exclusive financial advisor to Teva in the acquisition of German Specialty Generics Company AWD Pharmaceuticals.

Undisclosed terms.